Salvage radiation for a rising PSA following radical prostatectomy

Urologic Oncology: Seminars and Original Investigations

Volumn 22, Issue 1, 2004, Pages 50-56

  Maier, Jordan ^a   Forman, Jeffrey ^a   Tekyi Mensah, Samuel ^a   Bolton, Susan ^a   Patel, Rajiv ^a   Pontes, J Edson ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Postprostatectomy; Prostate cancer; Salvage radiation

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; BLOOD LEVEL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; DISEASE SEVERITY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LIGHT; MAJOR CLINICAL STUDY; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; NEUTRON RADIATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RADIATION DOSE; RADIATION INJURY; SALVAGE THERAPY; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

AGED; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 2142717334     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2003.12.001     Document Type: Conference Paper

References (24)

1. Stephenson R.A. Population based prostate cancer trends in the PSA era data from the Surveillance, Epidemiology, and End Results (SEER) Program. Monogr Urol. 19:1988;1
2. Catalona W.J., Smith D.S. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 152:1994;1837-1842
3. Kupelian P.A., Katcher J., Levin H.S., et al. Stage T1-2 prostate cancer a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys. 37:1997;1043-1052
4. Anscher M.S., Cough R. Radiotherapy for a rising PSA after radical prostatectomy the first 10 years. Int J Radiat Oncol Biol Phys. 45:1999;357
5. Pisansky T.M., Kozelsky T.F., Myers R.P., et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 16:2000;845-850
6. Schild S.E., Pisansky T.M. The role of radiotherapy after radical prostatectomy. Urol Clin North Am. 28:(3):2001;629-637
7. Cox J.D., Gallagher M.J., Hammond E.H., et al. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol. 17:1999;1155
8. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597
9. Frazier H.A., Robertson J.E., Humphrey P.A., et al. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol. 149:1993;516-518
10. Jhaveri F.M., Zippe C.D., Klein E.A., et al. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer 10 year results. Urology. 54:1999;884-890
11. Moul J.W., Wu H., Sun L., et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery. 132:(2):2002;213-219
12. Salomen C.G., Flisak M.C., Olson, et al. Radical prostatectomy transrectal sonographic evaluation to assess for local recurrence. Radiology. 189:1993;713-719
13. Kramer S., Gorich J., Gottfried H.W., et al. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol. 70:1997;2041-2046
14. Cher M.L., Bianco F.J., Lam J.S., et al. Limited role of radionuclide bone scintigraphy in patients with prostate antigen elevations after radical prostatectomy. J Urol. 160:1998;1387
15. Kahn D., Williams R.D., Seldin D.W., et al. Radioimmunoscintigraphy with 111indium labeled CYT - 356 for the detection of occult prostate cancer recurrence. J Urol. 152:1994;1490
16. Pound C.R., Partin A.W., Epstein J.I., et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy patterns of recurrence and cancer control. Urol Clin North Am. 24:1997;395-406
17. Partin A.W., Pearson J.D., Landis P.K., et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasis. Urology. 43:1994;649-659
18. Patel A., Dorey F., Franklin J., et al. Recurrence patterns after radical retropubic prostatectomy clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 158:1997;1441-1445
19. Youssef E., Tekyi-Mensah S., Hart K., et al. The prognostic significance of changes in prostatic specific antigen (PSA) levels during the course of therapeutic post prostatectomy irradiation. 1999;. Presented at the American Society for Therapeutic Radiation Oncology, San Antonio, Texas, November
20. Morris M.M., Dallow K.C., Zietman A.L., et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 38:(4):1997;731-736
21. Leventis A.K., Shariat S.F., Kattan M.W., et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 19:(4):2001;1030-1039
22. Wu J.J., King S.C., Montana G.S., et al. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate specific antigen. Int J Radiat Oncol Biol Phys. 32:(2):1995;317-323
23. Forman J.D., Duclos M., Shamsa F., et al. Predicting the need for adjuvant systemic therapy in patients receiving post prostatectomy irradiation. Urology. 47:(3):1996;382-386
24. Garg M.K., Tekyi-Mensah S., Bolton S., et al. Impact of post prostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology. 51:(6):1998;998-1002